Glidiab

Country of origin: Russia
Pharm-Group: Antidiabetic agents - sulfonylurea derivatives

Manufacturers: Akrikhin HFC (Russia)
International name: Gliclazide
Synonyms: Vero-Gliclazide, Glidiab MV, Glizide, Gliclazide, Gliclazide-Akos, Glioral, Diabest, Diabeton, Diabeton MV, Diabepharm, Diabinax, Diabrezide, Diatika, Medoklacid, Predian, Reklid
Dosage forms: tablets 80 mg
Composition: Active substance - gliclazide.

Indications for use: Diabetes mellitus type 2, monotherapy and in combination with insulin or other oral hypoglycemic drugs.
Contraindications: Hypersensitivity, type 1 diabetes mellitus, incl. juvenile, ketoacidosis, diabetic (with ketoacidosis) and hyperosmolar coma, extensive trauma and burns, liver failure and severe forms of renal failure, hypo- and hyperthyroidism, pregnancy, breastfeeding.
Side effects: From the gastrointestinal tract: very rarely - dyspeptic symptoms (nausea, vomiting, abdominal pain), jaundice. From the cardiovascular system and blood: reversible cytopenia, eosinophilia, anemia. From the skin: allergic skin reactions, photosensitivity. Metabolism: hypoglycemia. From the nervous system and sensory organs: weakness, headache, dizziness, changes in taste.

Interaction: The effect is enhanced by ACE inhibitors, anabolic steroids, beta-blockers, fibrates, biguanides, chloramphenicol, cimetidine, coumarins, fenfluramine, fluoxetine, salicylates, guanethidine, MAO inhibitors, miconazole, fluconazole, pentoxifylline, theophylline, phenylbutazone, phosphamides, tetracyclines . Barbiturates, chlorpromazine, glucocorticoids, sympathomimetics, glucagon, saluretics, rifampicin, thyroid hormones, lithium salts, high doses of nicotinic acid, oral contraceptives and estrogens - reduce hypoglycemia.

Overdose: Symptoms: hypoglycemic states, even coma, cerebral edema. Treatment: oral glucose, if necessary, intravenous administration of glucose solution (50%, 50 ml). Monitoring the level of glucose, urea nitrogen, electrolytes in the blood serum. With cerebral edema -
Special instructions: During dose selection, especially when combined with insulin therapy, it is necessary to determine the sugar profile and glycemic dynamics; in the future, regular monitoring of blood glucose levels is indicated. To prevent hypoglycemia, it is necessary to clearly time the drug intake with meals, avoid fasting and completely stop drinking alcohol. Concomitant use of beta-blockers may mask the symptoms of hypoglycemia. It is recommended to follow a low-calorie, low-carbohydrate diet. Use with caution while working for vehicle drivers and people whose profession involves increased concentration of attention.

Literature: Encyclopedia of Medicines, 10th edition, 2003.